This dual mechanismreduced hunger signals plus physical fullnesscreates a powerful synergy that changes not just how much you eat, but how you think about eating
This can be identified through tell-tale symptoms
Image Credit: Nefedova Tanya / Shutterstock A recent study published in The Lancet evaluated the safety and efficacy of oral semaglutide in people with early Alzheimers disease (AD)
What makes this research study very interesting indeed is that they discovered that semaglutide changes the metabolic pathway that cells use to make energy from sugars
But theres no data showing how well it works in humans, and the long-term safety of this peptide in humans is simply unknown
Your GLP-1 prescription qualifies when it is treating one of these documented conditions: Type 2 diabetes Clinical obesity with a comorbidity (hypertension, sleep apnea, cardiovascular disease, or high cholesterol) Prediabetes or insulin resistance Polycystic ovary syndrome (PCOS) Non-alcoholic fatty liver disease (NAFLD) The critical requirement is documentation